[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350969-105":59,"doc-detail-350969-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-computational-pathology-model-to-predict-docetaxel-benefit-in-localized-high-risk-and-metastatic-prostate-cancer","A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer","","Docetaxel improves survival in metastatic hormone-sensitive prostate cancer and in high-risk localized prostate cancer, yet patient benefit varies and predictive biomarkers remain limited. An artificial intelligence-based pathology image classifier (APIC) was developed and validated using digitized hematoxylin and eosin biopsy specimens from two phase 3 trials. APIC captured tumor–immune spatial interactions and nuclear heterogeneity to stratify overall survival and delay castration resistance with Cox models, including treatment–APIC interactions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-computational-pathology-model-to-predict-docetaxel-benefit-in-localized-high-risk-and-metastatic-prostate-cancer/350969/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-computational-pathology-model-to-predict-docetaxel-benefit-in-localized-high-risk-and-metastatic-prostate-cancer/350969.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is a predictive biomarker needed for docetaxel in prostate cancer?","Question",{"text":112,"@type":113},"Docetaxel improves outcomes, but benefits vary substantially among patients. Without biomarkers, clinicians cannot identify responders and patients may face unnecessary toxicity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does APIC predict docetaxel benefit?",{"text":117,"@type":113},"APIC is an AI-based pathology image classifier built from digitized H&E biopsy images. It uses features reflecting tumor–immune spatial interactions and nuclear heterogeneity, then is evaluated for effects on overall survival and castration resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding APIC-positive versus APIC-negative patients?",{"text":121,"@type":113},"In CHAARTED, APIC-positive patients showed significant overall survival improvement and delayed castration resistance, while APIC-negative patients showed no benefit. In NRG/RTOG 0521, APIC-positive patients demonstrated survival benefit and treatment–APIC interactions were significant.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350969,1790334275,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer  \nSebastian Medina1, Naoto Tokuyama1, Kamal Hammouda1,2,3, Tilak Pathak1, Tuomas Mirtti4, Pingfu Fu5, Shilpa Gupta6, Priti Lal7, Howard M. Sandler8, Rohann Correa9, Susan Chafe10, Amit Shah11,  \nJason A. Efstathiou12, Karen Hoffman13, Michael Straza14, Mark A. Hallman15, Richard Jordan16, Stephanie L. Pugh17, Christopher J. Sweeney18, and Anant Madabhushi1,2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Docetaxel improves survival in metastatic hormonesensitive prostate cancer (mHSPC) and high-risk localized disease, but benefits vary substantially among patients. Without predictive biomarkers, clinicians cannot identify patients who will benefit, exposing many to unnecessary toxicity. We developed and validated an artificial intelligence– based pathology image classifier (APIC) to predict docetaxel benefit.\u003Cbr>Experimental Design: We analyzed digitized hematoxylin and eosin–stained biopsy specimens from two phase 3 trials: CHAARTED (286/790 patients with mHSPC) and NRG/ RTOG 0521 (350/563 patients with high-risk localized disease) . APIC used features capturing tumor-immune spatial interactions and nuclear heterogeneity. We evaluated the predictive value of APIC for docetaxel benefit on overall survival (OS) and castration resistance using Cox proportional hazards with interaction terms.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: In CHAARTED, APIC-positive patients (56.7%) showed significant OS improvement with docetaxel [HR, 0.52; 95% confidence interval (CI), 0.31–0.85; P ¼ 0.008] and delayed castration resistance (HR, 0.48; 95% CI, 0.33–0.71; P \u003C 0.001), whereas APIC-negative patients (43.3%) showed no benefit (HR, 1.31; 95% CI, 0.71– 2.44; P ¼ 0.39). Treatment–APIC interactions were significant (P ¼ 0.022 and P ¼ 0.031). In NRG/RTOG 0521, APIC-positive patients (44.7%) demonstrated survival benefit (HR, 0.49; 95% CI, 0.26–0.92; P ¼ 0.023), whereas APIC-negative patients (55.3%) showed no benefit. Treatment–APIC interaction was significant (P ¼ 0.024). Predictive value remained significant after adjusting for clinical variables. Limitations include retrospective analysis and need for prospective validation.\u003Cbr>Conclusions: APIC predicts docetaxel benefit in both metastatic and localized prostate cancers, independent of clinical factors. Validation in triplet therapy with androgen receptor pathway inhibitors is needed. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nDocetaxel plays a significant and long-standing role in the treatment of prostate cancer because its efficacy has been demonstrated in patients with castration-resistant prostate cancer (CRPC) . Since the CHAARTED (1, 2) and STAMPEDE (3) trials, there has been consistent evidence that early docetaxel treatment significantly improves outcomes in patients w","cbCaic4PlHpupHuF","https://ap.wps.com/l/cbCaic4PlHpupHuF","pdf",14168202,"English","# Purpose\n# Experimental Design\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"Why is a predictive biomarker needed for docetaxel in prostate cancer?\",\"answer\":\"Docetaxel improves outcomes, but benefits vary substantially among patients. Without biomarkers, clinicians cannot identify responders and patients may face unnecessary toxicity.\"},{\"question\":\"How does APIC predict docetaxel benefit?\",\"answer\":\"APIC is an AI-based pathology image classifier built from digitized H\\u0026E biopsy images. It uses features reflecting tumor–immune spatial interactions and nuclear heterogeneity, then is evaluated for effects on overall survival and castration resistance.\"},{\"question\":\"What were the main findings regarding APIC-positive versus APIC-negative patients?\",\"answer\":\"In CHAARTED, APIC-positive patients showed significant overall survival improvement and delayed castration resistance, while APIC-negative patients showed no benefit. In NRG/RTOG 0521, APIC-positive patients demonstrated survival benefit and treatment–APIC interactions were significant.\"}]","A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer | PDF",1790092113,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76c948b8c12464f7f8db2ea4212b5b64.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1fd6d30877a63a683af764f6d86f0fb.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5740eae8f96be0c63293cee47df25913.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96e35d220ed260e34402c22738277e7a.webp",980,1311]